FDA Updates its Thinking on Immunogenicity Studies for Insulin Biosimilars, Interchangeables

As the cost of insulin continues to force some to ration their lifesaving drugs, the US Food and Drug Administration (FDA) on Monday released new draft guidance to help sponsors bring insulin biosimilars and interchangeable products to market more quickly.